Solasia Pharma K.K. Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	429	316	617	1,092	559
Revenue Growth (YoY)	35.76%	-48.78%	-43.50%	95.35%	23.13%
Cost of Revenue	221	131	280	430	185
Gross Profit	208	185	337	662	374
Selling, General & Admin	637	1,721	1,073	2,250	1,948
Research & Development	430	414	403	883	845
Operating Expenses	1,067	2,135	1,476	3,133	2,793
Operating Income	-859	-1,950	-1,139	-2,471	-2,419
Interest Expense	-14	-5	-	-18	-23
Interest & Investment Income	1	-	10	-	-
Earnings From Equity Investments	-1	-4	-5	-3	-
Other Non Operating Income (Expenses)	-3	-1	-1	-	-1
Pretax Income	-876	-1,960	-1,135	-2,492	-2,443
Income Tax Expense	-	-19	-23	56	35
Net Income	-876	-1,941	-1,112	-2,548	-2,478
Net Income to Common	-876	-1,941	-1,112	-2,548	-2,478
Shares Outstanding (Basic)	238	199	168	152	130
Shares Outstanding (Diluted)	238	199	168	152	130
Shares Change (YoY)	19.53%	18.18%	10.62%	16.78%	10.88%
EPS (Basic)	-3.69	-9.77	-6.61	-16.76	-19.04
EPS (Diluted)	-3.69	-9.77	-6.62	-16.77	-19.04
Free Cash Flow	-847	-1,034	-359	-2,074	-2,475
Free Cash Flow Per Share	-3.57	-5.20	-2.13	-13.65	-19.02
Gross Margin	48.48%	58.54%	54.62%	60.62%	66.91%
Operating Margin	-200.23%	-617.09%	-184.60%	-226.28%	-432.74%
Profit Margin	-204.20%	-614.24%	-180.23%	-233.33%	-443.29%
Free Cash Flow Margin	-197.44%	-327.21%	-58.18%	-189.93%	-442.75%
EBITDA	-822	-1,755	-639	-1,937	-1,924
EBITDA Margin	-191.61%	-	-103.57%	-177.38%	-
D&A For EBITDA	37	195	500	534	495
EBIT	-859	-1,950	-1,139	-2,471	-2,419
EBIT Margin	-200.23%	-	-184.60%	-226.28%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.